Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 3/20 | 0.46 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.45 |
| ▸ | GLS | O94925 | 1/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27787157 | 0.89 | CYP17A1 (0.57) | CYP17A1DRD2PTGDR2MAPK14NAMPT | |
| SCHEMBL6932894 | 0.86 | CYP17A1 (0.54) | CYP17A1DRD2PTGDR2MAPK14NAMPT | |
| SCHEMBL132701 | 0.85 | CYP17A1 (0.76) | CYP17A1DRD2PTGDR2MAPK14NAMPT | |
| SCHEMBL13055402 | 0.84 | CYP17A1 (0.59) | CYP17A1DRD2PTGDR2MAPK14NAMPT | |
| SCHEMBL22425202 | 0.84 | CYP17A1 (0.58) | CYP17A1DRD2PTGDR2MAPK14NAMPT | |
| SCHEMBL27549443 | 0.84 | CYP17A1 (0.52) | CYP17A1DRD2PTGDR2MAPK14NAMPT | |
| SCHEMBL10361607 | 0.83 | CYP17A1 (0.61) | CYP17A1DRD2PTGDR2MAPK14NAMPT | |
| SCHEMBL6195004 | 0.83 | CYP17A1 (0.61) | CYP17A1DRD2PTGDR2MAPK14NAMPT | |
| SCHEMBL245094 | 0.83 | CYP17A1 (0.61) | CYP17A1DRD2PTGDR2MAPK14NAMPT | |
| SCHEMBL5541426 | 0.83 | CYP17A1 (0.54) | CYP17A1DRD2PTGDR2MAPK14NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103232352-B | (R)-4-(2-(2-hydroxyl-2-phenylethylamine base) ethyl) anilino carboxylate | SUZHOU UUGENE BIOPHARMA CO., LTD. (CN) | 2015-12-23 | — | — | CN | claimed |
| CN-103232352-A | (R)-4-(2-(2-hydroxyl-2-phenylethylamino)-ethyl) tert-butyl phenylcarbamate | SUZHOU UUGENE BIOPHARMA CO LTD | 2013-08-07 | — | — | CN | claimed |
| WO-2025059577-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS FOR USE AS AKT1 INHIBITORS | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| WO-2024059808-A1 | WEE1 INHIBITORS AND METHODS FOR TREATING CANCER | RECURIUM IP HOLDINGS, LLC (US) | 2024-03-21 | — | — | WO | disclosed |
| US-11918656-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2024-03-05 | — | — | US | disclosed |
| US-11661457-B2 | IGF-1R antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2023-05-30 | — | — | US | disclosed |
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2023-01-05 | — | — | US | disclosed |
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2023-01-05 | — | — | US | disclosed |
| EP-3607996-B1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2023-01-04 | — | — | EP | disclosed |
| EP-3607996-B1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2023-01-04 | — | — | EP | disclosed |
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2022-12-06 | — | — | US | disclosed |
| US-8003627-B2 | Urokinase inhibitors | UNIVERSITEIT ANTWERPEN (BE) | 2011-08-23 | — | — | US | disclosed |
| US-20100273755-A1 | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-10-28 | — | — | US | disclosed |
| WO-2010123766-A1 | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | THERAVANCE, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20080312191-A1 | Novel Urokinase Inhibitors | UNIVERSITEIT ANTWERPEN (BE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312191-A1 | Novel Urokinase Inhibitors | UNIVERSITEIT ANTWERPEN (BE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312191-A1 | Novel Urokinase Inhibitors | UNIVERSITEIT ANTWERPEN (BE) | 2008-12-18 | — | — | US | disclosed |
| EP-1940856-A1 | NOVEL UROKINASE INHIBITORS | Universiteit Antwerpen (BE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007045496-A1 | NOVEL UROKINASE INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045496-A1 | NOVEL UROKINASE INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DDOST, DAD1, KRTCAP2 | CYP17A1 1563/4885DRD2 2799/4885PTGDR2 4090/4885 |
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | NR1H4, HCAR3, VDR | CYP17A1 762/4885DRD2 1866/4885PTGDR2 1231/4885 |
| US-11918656-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DDOST, DAD1, KRTCAP2 | CYP17A1 1563/4885DRD2 2799/4885PTGDR2 4090/4885 |
| US-20080312191-A1 | Novel Urokinase Inhibitors | PLAU, PLAUR, SERPINE1 | CYP17A1 3160/4885DRD2 4291/4885PTGDR2 2177/4885 |
| US-11661457-B2 | IGF-1R antibody-drug-conjugate and its use for the treatment of cancer | IGF1R, IGFBP1, IGFBP5 | CYP17A1 1069/4885DRD2 3040/4885PTGDR2 3505/4885 |
| US-20100273755-A1 | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2A | CYP17A1 1410/4885DRD2 59/4885PTGDR2 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.